1.Clinical Outcome of a Rectovaginal Fistula in Crohn's Disease.
Choon Sik CHUNG ; Dong Keun LEE ; Bruce D GEORGE ; Neil J MORTENSEN
Journal of the Korean Society of Coloproctology 2007;23(1):10-15
PURPOSE: The aim of this study is to analyze the outcome of a variety of treatments, including local surgical treatments, diverting stoma, and combined medical therapy, for patients with a rectovaginal fistula complicating Crohn's disease. METHODS: Between 1994 and 2003, twenty-one patients with a rectovaginal fistula complicating Crohn's disease from a prospectively compiled 422-patient Crohn's disease database were reviewed. RESULTS: All three patients treated by seton and fibrin glue recurred despite having relatively long tracts. Of six patients with infliximab treatment combined with a seton procedure, five patients had an improvement of their symptoms, but were not cured. Of eight patients with a transanal or endovaginal advancement flap techniques, three had successful closure, three eventually required a proctectomy, and two had a recurrent fistula without symptoms. Four (2 without any local treatments, and 2 with seton placement) of 16 patients who had a diverting stoma during treatment had successful closure. All proctectomy patients (n=8) had rectal involvement of Crohn's disease. Two patients who underwent a proctectomy with a presumptive diagnosis of ulcerative colitis and indeterminate colitis turned out to have Crohn's disease. Overall, except for the proctectomy patients, seven patients (54%) had successful closure, but six (four without symptoms, and two with symptoms) following a wide spectrum of treatments had recurrence after a mean follow-up of 44 months. CONCLUSIONS: Combining different treatments for a rectovaginal fistula in Crohn's disease can be successful in a reasonable number of cases. The presence of uncontrolled perianal sepsis and/or complicated anorectal problems is likely to lead to a proctectomy.
Colitis
;
Colitis, Ulcerative
;
Crohn Disease*
;
Diagnosis
;
Fibrin Tissue Adhesive
;
Fistula
;
Follow-Up Studies
;
Humans
;
Infliximab
;
Rectovaginal Fistula*
;
Recurrence
;
Sepsis